Home › Lupus

Lupus clinical trials recruiting in the U.S.

73 studies for Lupus are recruiting participants at sites across the United States.

Lupus is an autoimmune disease that causes your immune system to attack your healthy tissues and cells. This can cause damage to many parts of your body.

Cities with the most studies

• New York City, NY18 studies
• Houston, TX13 studies
• Durham, NC12 studies
• Washington, DC10 studies
• Miami, FL10 studies
• Tampa, FL9 studies
• Philadelphia, PA9 studies
• Clearwater, FL8 studies
• Santa Monica, CA8 studies
• Oklahoma City, OK8 studies
• Boston, MA8 studies
• Los Angeles, CA8 studies
• Chicago, IL8 studies
• Memphis, TN7 studies
• San Diego, CA7 studies
• Buena Park, CA7 studies
• Charlotte, NC7 studies
• Plantation, FL7 studies
• Hollywood, FL6 studies
• Aurora, CO6 studies
• Dallas, TX6 studies
• Cedar Rapids, IA6 studies
• Atlanta, GA6 studies
• Cicero, IL5 studies
• Lake Charles, LA5 studies
• Cleveland, OH5 studies
• New Orleans, LA5 studies
• Jackson, TN5 studies
• Fullerton, CA5 studies
• St. Louis, MO5 studies
• Orlando, FL5 studies
• Syracuse, NY5 studies
• Coral Springs, FL4 studies
• Rochester, NY4 studies
• Arlington, TX4 studies
• Allen, TX4 studies
• Flint, MI4 studies
• Brandon, FL4 studies
• Louisville, KY4 studies
• Phoenix, AZ4 studies

By state

• Alabama5 studies
• Arizona7 studies
• California27 studies
• Colorado8 studies
• District of Columbia5 studies
• Florida23 studies
• Georgia9 studies
• Illinois14 studies
• Indiana4 studies
• Iowa6 studies
• Kansas5 studies
• Kentucky4 studies
• Louisiana9 studies
• Maryland10 studies
• Massachusetts9 studies
• Michigan10 studies
• Minnesota5 studies
• Missouri8 studies
• Nebraska3 studies
• New Jersey6 studies
• New York26 studies
• North Carolina20 studies
• Ohio11 studies
• Oklahoma8 studies
• Pennsylvania14 studies
• South Carolina5 studies
• Tennessee13 studies
• Texas26 studies
• Utah4 studies
• Virginia3 studies
• Washington5 studies

Recently updated studies

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.